Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 14, 2021	Oct. 02, 2021	Sep. 30, 2021	Sep. 29, 2021	Feb. 02, 2021
Debt Instrument, Face Amount						$ 840,000
Shares price	$ 1.75	$ 2.00	$ 4.00	$ 3.00	$ 1.25
Convertible Notes Payables [Member]
Debt Conversion, Converted Instrument, Amount	$ 2,658,960
Interest rate discount	4,906,415
Financing fees paid	1,086,095
Convertible Notes Payables [Member] | Warrant [Member]
Debt Conversion, Converted Instrument, Amount	3,703,134
A H A [Member]
Debt Discount (Premium)	7,565,375
A H A [Member] | Individuals [Member]
Debt Conversion, Converted Instrument, Amount	3,904,221
Debt Instrument, Face Amount	$ 7,565,375
Shares price	$ 1.55
Debt Discount (Premium)	$ 3,904,221
Accreted balance	$ 1,820,000
Common stock shares	1,173,834
A H A [Member] | Investor [Member]
Debt Conversion, Converted Instrument, Amount	$ 575,000
Merger transaction description	The note was entered into on August 25, 2020 and was convertible into AHA’s common stock contingent upon a merger transaction with a SPAC, which did not close. Under an Agreement with the investor signed on April 20, 2021, the Note was deemed to mature as of December 31, 2020 and accrued penalty interest was assessed through April 15, 2021 when the Note (including accrued interest) was to be converted into 625,313 shares of Clinigence common stock consisting of principal of $575,000 and penalty interest of $50,313, valued at $1.00 per share. On September 30, 2021, the Company entered into a promissory note settlement agreement whereby the noteholder converted the principal balance of $575,000 into 191,667 common shares valued at $3.00 per share, and the Company paid $51,750 of accrued interest to the noteholder